KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Receivables (2016 - 2025)

Historic Receivables for NovoCure (NVCR) over the last 12 years, with Q3 2025 value amounting to $46.7 million.

  • NovoCure's Receivables fell 3579.2% to $46.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.7 million, marking a year-over-year decrease of 3579.2%. This contributed to the annual value of $40.8 million for FY2024, which is 5147.06% up from last year.
  • NovoCure's Receivables amounted to $46.7 million in Q3 2025, which was down 3579.2% from $96.9 million recorded in Q2 2025.
  • In the past 5 years, NovoCure's Receivables registered a high of $101.0 million during Q1 2022, and its lowest value of $17.0 million during Q4 2021.
  • In the last 5 years, NovoCure's Receivables had a median value of $74.8 million in 2023 and averaged $69.4 million.
  • In the last 5 years, NovoCure's Receivables skyrocketed by 41954.77% in 2022 and then tumbled by 6955.67% in 2023.
  • Quarter analysis of 5 years shows NovoCure's Receivables stood at $17.0 million in 2021, then soared by 419.55% to $88.5 million in 2022, then crashed by 69.56% to $26.9 million in 2023, then skyrocketed by 51.47% to $40.8 million in 2024, then increased by 14.61% to $46.7 million in 2025.
  • Its last three reported values are $46.7 million in Q3 2025, $96.9 million for Q2 2025, and $91.1 million during Q1 2025.